These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. DNA topoisomerase I poisons. Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479 [No Abstract] [Full Text] [Related]
6. DNA topoisomerases and topoisomerase inhibitors. Giaccone G Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789 [TBL] [Abstract][Full Text] [Related]
7. DNA-topoisomerase I and II: biologic features and their role in drug resistance. Russo D; Marie JP; Delmer A; Zhou D; Suberville AM; Baccarani M; Zittoun R Haematologica; 1993; 78(4):201-7. PubMed ID: 8294050 [No Abstract] [Full Text] [Related]
8. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Beck WT; Danks MK Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118 [TBL] [Abstract][Full Text] [Related]
9. Topoisomerases, new targets in cancer chemotherapy. Zijlstra JG; de Jong S; de Vries EG; Mulder NH Med Oncol Tumor Pharmacother; 1990; 7(1):11-8. PubMed ID: 2160032 [TBL] [Abstract][Full Text] [Related]
10. Using yeast to understand drugs that target topoisomerases. Nitiss JL; Rose A; Sykes KC; Harris J; Zhou J Ann N Y Acad Sci; 1996 Dec; 803():32-43. PubMed ID: 8993498 [No Abstract] [Full Text] [Related]
11. Drugs acting on DNA topoisomerases: recent advances and future perspectives. Gatto B; Capranico G; Palumbo M Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890 [TBL] [Abstract][Full Text] [Related]
12. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors]. Ishida R; Andoh T Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to topoisomerases poisons. Prost S Gen Pharmacol; 1995 Dec; 26(8):1773-84. PubMed ID: 8745168 [TBL] [Abstract][Full Text] [Related]
14. Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Pommier Y Semin Oncol; 1996 Feb; 23(1 Suppl 3):3-10. PubMed ID: 8633251 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 1,5-naphthyridines as topoisomerase I inhibitors. A new family of antiproliferative agents. Alonso C; Fuertes M; González M; Rodríguez-Gascón A; Rubiales G; Palacios F Curr Top Med Chem; 2014; 14(23):2722-8. PubMed ID: 25515747 [TBL] [Abstract][Full Text] [Related]
16. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Sinha BK Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211 [TBL] [Abstract][Full Text] [Related]
17. DNA topoisomerases as targets for anticancer drugs. Topcu Z J Clin Pharm Ther; 2001 Dec; 26(6):405-16. PubMed ID: 11722677 [TBL] [Abstract][Full Text] [Related]
18. [DNA topoisomerases and resistance to anticancer agents]. Andoh T; Okada K Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):569-75. PubMed ID: 2539786 [TBL] [Abstract][Full Text] [Related]
19. Topoisomerase I inhibitors. An overview of the camptothecin analogs. Burris HA; Fields SM Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144 [TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]